EUCTR2013-004167-32-GR进行中（未招募）1 期
A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improveddeferasirox formulation (film-coated tablet)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent/assent before any study-specific procedures. For pediatric patients, consent will be obtained from parent(s) or legal patient’s representative. Investigators will also obtain assent of patients according to local, regional or national guidelines.
- •2. Male and female patients aged = 10 years
- •3. Patients with transfusion-dependent thalassemia and iron overload, requiring deferasirox DT at doses of = 30 mg/kg/day as per the investigator’s decision
- •Patients with very low, low or intermediate (int-1) risk myelodysplastic syndrome (MDS) and iron overload, requiring deferasirox DT at doses of = 20 mg/kg/day as per the investigator’s decision.
- •The very low, low or intermediate (int-1) risk MDS should be determined by the Revised International Prognostic Scoring System (IPSS-R) and IPSS-R must be confirmed by a bone marrow examination within 6 months prior to study entry and must be hematologically stable with a patient’s life expectancy of at least 1 year.
- •4. History of transfusion of at least 20 PRBC units and anticipated to be transfused with at least 8 units of PRBCs annually during the study
- •5. Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 105
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Creatinine clearance below the contraindication limit in the locally approved prescribing information. Creatinine clearance will be estimated from serum creatinine at screening Visit 1 and screening Visit 2 and the mean value will be used for eligibility criteria.
- •2. Serum creatinine > 1.5 xULN at screening measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria).
- •3. ALT (SGPT) > 5xULN, unless if LIC confirmed as <10 mg Fe/dw within 6 months prior to screening visit 1.
- •4. Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg in a non-first void urine sample at screening Visit 1 or screening Visit 2.
- •5. Patients with significant impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- •6. Clinical or laboratory evidence of active Hepatitis B or Hepatitis C (HBsAg in the absence of HBsAb OR HCV Ab positive with HCV RNA positive).
- •7. Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing any of the treatment options or patients unwilling or unable to comply with the protocol (including use of electronic devices for ePRO).
- •8. Patients with a known history of HIV seropositivity (Elisa or Western blot).
- •9. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
- •10. Patients participating in another clinical trial or receiving an investigational drug.
- •11. History of hypersensitivity to any of the study drug or excipients.
- •12. Significant medical condition interfering with the ability to partake in this study (e.g. systemic uncontrolled hypertension, unstable cardiac disease not controlled by standard medical therapy, systemic disease (cardiovascular, renal, hepatic, etc.).
- •13. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.
- •14. Sexually active males unless they use a condom during intercourse while taking drug and
- •for 28 days after stopping study medication and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
研究者
相似试验
进行中（未招募）
1 期
A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improveddeferasirox formulation (film-coated tablet)transfusion-dependent thalassemia or myelodysplastic syndrome at very low, low or intermediate (int-1) riskMedDRA version: 17.0Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 17.0Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864EUCTR2013-004167-32-FRovartis Pharma Services AG150
进行中（未招募）
1 期
Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overloadEUCTR2013-004739-55-FRovartis Pharma Services AG240
进行中（未招募）
1 期
AEUCTR2013-004167-32-ITOVARTIS FARMA S.p.A150
进行中（未招募）
1 期
Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overloadEUCTR2013-004739-55-ITOVARTIS PHARMA SERVICES AG216
进行中（未招募）
1 期
Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overloadtransfusion-dependent anemia requiring chelation therapy due to iron overloadMedDRA version: 19.0Level: LLTClassification code 10074295Term: Transfusion dependent anemiaSystem Organ Class: 100000004851EUCTR2013-004739-55-DKovartis Pharma Services AG240